

Emergent BioSolutions Inc.
Form 4/A
September 14, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Michigan Biologic Products, Inc.

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [EBS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
5723 DELTA RIVER DRIVE

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2007

____ Director
____ Officer (give title below) 10% Owner
____ Other (specify below)
Member 13(d) group owning >10%

(Street)
LANSING, MI 48906

4. If Amendment, Date Original Filed (Month/Day/Year)
09/06/2007

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common Stock | 09/05/2007 | | S(1) | | 300 | D | \$ 8.6 1,926,650 (2) |
| Common Stock | 09/05/2007 | | S(1) | | 100 | D | \$ 8.61 1,926,550 (2) |
| Common Stock | 09/05/2007 | | S(1) | | 300 | D | \$ 8.62 1,926,250 (2) |
| Common Stock | 09/05/2007 | | S(1) | | 300 | D | \$ 8.64 1,925,950 (2) |
| Common Stock | 09/05/2007 | | S(1) | | 100 | D | \$ 8.71 1,925,850 (2) |

Edgar Filing: Emergent BioSolutions Inc. - Form 4/A

| | | | | | | | |
|--------------|------------|--------------|-------|---|---------|----------------------|---|
| Common Stock | 09/05/2007 | <u>S</u> (1) | 300 | D | \$ 8.72 | 1,925,550 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 200 | D | \$ 8.75 | 1,925,350 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 400 | D | \$ 8.77 | 1,924,950 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 400 | D | \$ 8.78 | 1,924,550 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 700 | D | \$ 8.79 | 1,923,850 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 1,211 | D | \$ 8.8 | 1,922,639 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 1,700 | D | \$ 8.81 | 1,920,939 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 889 | D | \$ 8.82 | 1,920,050 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 400 | D | \$ 8.83 | 1,919,650 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 100 | D | \$ 8.84 | 1,919,550 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 100 | D | \$ 8.85 | 1,919,450 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 100 | D | \$ 8.87 | 1,919,350 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 3,400 | D | \$ 8.9 | 1,915,950 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 500 | D | \$ 8.91 | 1,915,450 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 600 | D | \$ 8.92 | 1,914,850 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 200 | D | \$ 8.93 | 1,914,650 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 1,600 | D | \$ 8.94 | 1,913,050 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 800 | D | \$ 8.96 | 1,912,250 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 200 | D | \$ 8.97 | 1,912,050 <u>(2)</u> | D |
| Common Stock | 09/05/2007 | <u>S</u> (1) | 200 | D | \$ 8.99 | 1,911,850 <u>(2)</u> | D |
| | 09/05/2007 | <u>S</u> (1) | 100 | D | \$ 9 | 1,911,750 <u>(2)</u> | D |

Common
Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Michigan Biologic Products, Inc.
5723 DELTA RIVER DRIVE
LANSING, MI 48906

Member 13(d) group owning >10%

Signatures

/s/ Carl A. Valenstein, attorney
in fact

09/14/2007

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2007.
- (2) A Form 4 filed by the Reporting Person on September 6, 2007 incorrectly stated the amount of common stock sold on September 4, 2007 by the Reporting Person. An amendment to that Form 4 has been filed with the SEC to report the correct number of common stock sold (a lower number) and, correspondingly, corrects the number of common stock beneficially owned by the Reporting Person after such sales. Since the Reporting Person sold less common stock on September 4, 2007 than initially reported on its Form 4 on September 6, 2007,

Edgar Filing: Emergent BioSolutions Inc. - Form 4/A

after the correction, there is a correlative increase in the reported number of common stock beneficially owned by the Reporting Person. Accordingly, this Amendment corrects the number of common stock reported as beneficially owned by the Reporting Person after the sale transactions executed on September 5, 2007 and reported on September 6, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.